A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.

Jansson AK, Gómez-Martín M, Hedin L, Clarke ED, Cross V, Stanford J, Taylor RM, Bogl LH, De Vlieger N, Koochek A, Löf M, Asher RC and 5 more

Show all authors

Burrows T, Bucher T, Sullivan C, Nowicka P, Collins CE

Obesity reviews : an official journal of the International Association for the Study of Obesity5 Jan 2026Cited by 7 (Europe PMC)

PMID41491340DOI10.1111/obr.70077PepBankPUB-41491340

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone15

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewOther
In this review of liraglutide, semaglutide, and tirzepatide trials, only two adult studies assessed or reported dietary intake or diet changes.
In plain wordsIn the review of liraglutide, semaglutide and tirzepatide trials, only two adult studies reported diet intake or changes.
Peptide
Liraglutide
Outcome
Not applicableDietary intake reporting
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Measurements
Studies reporting dietary intake
2 studies
adult studies
Source sentences
Summary
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
3 context sentences(design, population, supporting numbers)
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4149134001
02HumanNot a test of Semaglutide aloneSystematic reviewOther
In this review of liraglutide, semaglutide, and tirzepatide trials, only two adult studies assessed or reported dietary intake or diet changes.
In plain wordsIn the review of liraglutide, semaglutide and tirzepatide trials, only two adult studies reported diet intake or changes.
Peptide
Semaglutide
Outcome
Not applicableDietary intake reporting
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Measurements
Studies reporting dietary intake
2 studies
adult studies
Source sentences
Summary
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
3 context sentences(design, population, supporting numbers)
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4149134002
03HumanNot a test of Tirzepatide aloneSystematic reviewOther
In this review of liraglutide, semaglutide, and tirzepatide trials, only two adult studies assessed or reported dietary intake or diet changes.
In plain wordsIn the review of liraglutide, semaglutide and tirzepatide trials, only two adult studies reported diet intake or changes.
Peptide
Tirzepatide
Outcome
Not applicableDietary intake reporting
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Measurements
Studies reporting dietary intake
2 studies
adult studies
Source sentences
Summary
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
3 context sentences(design, population, supporting numbers)
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4149134003
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had reduced energy intake, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups reduced energy intake; one did not differ significantly from medication alone.
Peptide
Liraglutide
Outcome
DecreaseTotal energy intake
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4149134004
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had reduced energy intake, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups reduced energy intake; one did not differ significantly from medication alone.
Peptide
Semaglutide
Outcome
DecreaseTotal energy intake
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4149134005
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had reduced energy intake, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups reduced energy intake; one did not differ significantly from medication alone.
Peptide
Tirzepatide
Outcome
DecreaseTotal energy intake
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4149134006
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had altered macronutrient distribution, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups altered macronutrient distribution; one did not differ significantly from medication alone.
Peptide
Liraglutide
Outcome
Direction not reportedMacronutrient distribution
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4149134007
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had altered macronutrient distribution, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups altered macronutrient distribution; one did not differ significantly from medication alone.
Peptide
Semaglutide
Outcome
Direction not reportedMacronutrient distribution
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4149134008
09HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In two adult studies in the liraglutide, semaglutide and tirzepatide review, medication-plus-diet groups had altered macronutrient distribution, although one did not differ significantly from medication alone.
In plain wordsIn two adult studies in the GLP-1/GIP medicine review, medication-plus-diet groups altered macronutrient distribution; one did not differ significantly from medication alone.
Peptide
Tirzepatide
Outcome
Direction not reportedMacronutrient distribution
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4149134009
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In one adult study in the liraglutide, semaglutide and tirzepatide review, the dietary result with medication plus diet did not differ significantly from medication alone.
In plain wordsIn one adult study in the GLP-1/GIP medicine review, the dietary result with medication plus diet did not differ significantly from medication alone.
Peptide
Liraglutide
Outcome
No significant changeDietary intake versus medication alone
Study
n: not reported in source
Comparator
Medication alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4149134010
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In one adult study in the liraglutide, semaglutide and tirzepatide review, the dietary result with medication plus diet did not differ significantly from medication alone.
In plain wordsIn one adult study in the GLP-1/GIP medicine review, the dietary result with medication plus diet did not differ significantly from medication alone.
Peptide
Semaglutide
Outcome
No significant changeDietary intake versus medication alone
Study
n: not reported in source
Comparator
Medication alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4149134011
12HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In one adult study in the liraglutide, semaglutide and tirzepatide review, the dietary result with medication plus diet did not differ significantly from medication alone.
In plain wordsIn one adult study in the GLP-1/GIP medicine review, the dietary result with medication plus diet did not differ significantly from medication alone.
Peptide
Tirzepatide
Outcome
No significant changeDietary intake versus medication alone
Study
n: not reported in source
Comparator
Medication alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4149134012
13HumanNot a test of Liraglutide aloneSystematic reviewOther
In the two reviewed adult studies reporting dietary data, dietary-assessment method quality was categorized as poor and acceptable, respectively.
In plain wordsIn this liraglutide, semaglutide and tirzepatide review, the two adult studies reporting diet data had assessments rated poor and acceptable.
Peptide
Liraglutide
Outcome
Not applicableDietary assessment method quality
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Source sentences
Summary
Quality of assessment methods used was categorized as "poor" and "acceptable," respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4149134013
14HumanNot a test of Semaglutide aloneSystematic reviewOther
In the two reviewed adult studies reporting dietary data, dietary-assessment method quality was categorized as poor and acceptable, respectively.
In plain wordsIn this liraglutide, semaglutide and tirzepatide review, the two adult studies reporting diet data had assessments rated poor and acceptable.
Peptide
Semaglutide
Outcome
Not applicableDietary assessment method quality
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Source sentences
Summary
Quality of assessment methods used was categorized as "poor" and "acceptable," respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4149134014
15HumanNot a test of Tirzepatide aloneSystematic reviewOther
In the two reviewed adult studies reporting dietary data, dietary-assessment method quality was categorized as poor and acceptable, respectively.
In plain wordsIn this liraglutide, semaglutide and tirzepatide review, the two adult studies reporting diet data had assessments rated poor and acceptable.
Peptide
Tirzepatide
Outcome
Not applicableDietary assessment method quality
Study
n: not reported in source
Outcome group
Appetite and food intake · Pharmacology
Source sentences
Summary
Quality of assessment methods used was categorized as "poor" and "acceptable," respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet.
Summary · context
This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality o…
Summary · context
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008-January 2025 (adults) and January 2014-January 2025 (children/adolescents).
Summary · context
Forty-three articles from 41 unique RCTs, comprising 50,690 participants (n = 688 children/adolescents, n = 50,002 adults) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4149134015

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.

Summary

Results from this study15

Studies that did not test the peptide alone15

Version history

Subjects

Publication types

MeSH terms

Keywords